export const referencesData = {
  "58": {
    text: "Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996 Jul 3;88(13):918–22.",
    url: "https://doi.org/10.1093/jnci/88.13.918"
  },
  "80": {
    text: "Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101–26.",
    url: "https://doi.org/10.1038/s41573-022-00595-0"
  },
  "81": {
    text: "Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb 1;25(2):e73–83.",
    url: "https://doi.org/10.1016/S1470-2045(23)00534-X"
  },
  "116": {
    text: "Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, et al. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiother Oncol. 2024 Aug 1;197.",
    url: "https://doi.org/10.1016/j.radonc.2024.109962"
  },
  "162": {
    text: "Ivaldi GB, Leonardi M, Ferrari A, Morra A, Fossati BJ, Vavassori A, et al. Concomitant Radiotherapy and Anthracycline-based Chemotherapy in Adjuvant Breast Cancer Treatment. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):S180–1.",
    url: "https://www.redjournal.org/article/S0360-3016(08)01392-8/fulltext"
  },
  "164": {
    text: "Spittle MF. Methotrexate and radiation. Int J Radiat Oncol. 1978 Jan 1;4(1):103–7.",
    url: "https://doi.org/10.1016/0360-3016(78)90123-2"
  },
  "170": {
    text: "Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LJA. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2008 May 10;26(14):2405–6.",
    url: "https://doi.org/10.1200/jco.2007.15.8451"
  },
  "171": {
    text: "Guimond E, Tsai CJ, Hosni A, O'Kane G, Yang J, Barry A. Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. Adv Radiat Oncol. 2022 Jul 14;7(6):101022.",
    url: "https://doi.org/10.1016/j.adro.2022.101022"
  },
  "178": {
    text: "Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632–46.",
    url: "https://doi.org/10.1016/j.ijrobp.2016.01.038"
  },
  "184": {
    text: "Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022 Dec 1;8(12):1802–8.",
    url: "https://doi.org/10.1001/jamaoncol.2022.5074"
  },
  "185": {
    text: "Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989 Feb 1;49(3):605–12.",
    url: "https://doi.org/10.1073/pnas.86.13.4963"
  },
  "186": {
    text: "Einhorn L, Krause M, Hornback N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer. 1976 May;37(5):2414–6.",
    url: "https://doi.org/10.1002/1097-0142(197605)37:5%3C2414::aid-cncr2820370533%3E3.0.co;2-j"
  },
  "187": {
    text: "Vermund H, Kaalhus O, Winther F, Trausjø J, Thorud E, Harang R. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys. 1985 Nov 1;11(11):1877–86.",
    url: "https://doi.org/10.1016/0360-3016(85)90267-6"
  },
  "188": {
    text: "Matsuoka K, Kobunai T, Nukatsuka M, Takechi T. Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro. Biochem Biophys Res Commun. 2017 Dec 9;494(1–2):249–55.",
    url: "https://doi.org/10.1016/j.bbrc.2017.10.052"
  },
  "189": {
    text: "Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, et al. Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clin Colorectal Cancer. 2024 Jun 22",
    url: "https://doi.org/10.1016/j.clcc.2024.06.003"
  },
  "190": {
    text: "Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martinez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Jul;4(7):845–52.",
    url: "https://doi.org/10.1097/jto.0b013e3181a97e17"
  },
  "191": {
    text: "Iglseder S, Nowosielski M, Bsteh G, Muigg A, Heugenhauser J, Mayer E, et al. Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 May;198(5):475–83.",
    url: "https://doi.org/10.1007/s00066-022-01910-9"
  },
  "192": {
    text: "Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer Amst Neth. 2015 Mar;87(3):232–40.",
    url: "https://doi.org/10.1016/j.lungcan.2014.12.003"
  },
  "193": {
    text: "Botwood N, James R, Vernon C, Price P. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2000 Aug;11(8):1023–8.",
    url: "https://doi.org/10.1023/a:1008376306429"
  },
  "194": {
    text: "Martin DS, Kligerman MM, Fugmann RA. Radiotherapy and Adjuvant Combination Chemotherapy (6-Aminonicotinamide and 6-Mercaptopurine). Cancer Res. 1958 Sep 1;18(8_Part_1):893–6.",
    url: "https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://pubmed.ncbi.nlm.nih.gov/13573360/&ved=2ahUKEwi66uilyNqLAxXLTKQEHYyIMIEQFnoECBUQAQ&usg=AOvVaw2wTIX5ZRNpb3igjNM0nOz7"
  },
  "195": {
    text: "Nitsche M, Christiansen H, Lederer K, Griesinger F, Schmidberger H, Pradier O. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol. 2012 Jul;138(7):1113–20.",
    url: "https://doi.org/10.1007/s00432-012-1185-3"
  },
  "196": {
    text: "Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019 Nov;25(11):2211–6.",
    url: "https://doi.org/10.1016/j.bbmt.2019.06.017"
  },
  "197": {
    text: "Cariveau MJ, Stackhouse M, Cui XL, Tiwari K, Waud W, Secrist JA, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):213–20.",
    url: "https://doi.org/10.1016/j.ijrobp.2007.09.012"
  },
  "198": {
    text: "El Cheikh J, Bidaoui G, Atoui A, Terro K, Sharrouf L, Zahreddine A, et al. Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. Bone Marrow Transplant. 2023 Jun;58(6):667–72.",
    url: "https://www.nature.com/articles/s41409-023-01947-z#citeas"
  },
  "199": {
    text: "Hetzel FW, Brown M, Kaufman N, Bicher HI. Radiation sensitivity modification by chemotherapeutic agents. Cancer Clin Trials. 1981;4(2):177–82.",
    url: "https://pubmed.ncbi.nlm.nih.gov/7249254/"
  },
  "200": {
    text: "Cailleteau A, Maingon P, Choquet S, Bourdais R, Antoni D, Lioure B, et al. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):677–85.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.09.069"
  },
  "201": {
    text: "Zachariae C, Overgaard J. Interactions of radiation, cyclophosphamide and nimorazole in a C3H mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1445–8.",
    url: "https://doi.org/10.1016/0360-3016(86)90191-4"
  },
  "202": {
    text: "Byar D, Kenis Y, Van Andel JG, de Jong M, Laval P, Marion L, et al. Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results. Eur J Cancer 1965. 1978 Sep 1;14(9):919–30.",
    url: "https://doi.org/10.1016/0014-2964(78)90018-x"
  },
  "203": {
    text: "Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol Lond Engl. 2010 Jun 16;5:55.",
    url: "https://doi.org/10.1186/1748-717x-5-55"
  },
  "204": {
    text: "Spalek MJ, Koseła-Paterczyk H, Borkowska A, Wagrodzki M, Szumera-Cieckiewicz A, Czarnecka AM, et al. Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol. 2021 Jul 15;110(4):1053–63.",
    url: "https://doi.org/10.1016/j.ijrobp.2021.02.019"
  },
  "205": {
    text: "Nahi H, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. Eur J Haematol. 2014;92(5):454–5.",
    url: "https://doi.org/10.1111/ejh.12247"
  },
  "206": {
    text: "Pan E, Yu D, Zhao X, Neuger A, Smith P, Chinnaiyan P, et al. Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. J Neurooncol. 2014 Sep;119(2):413–20.",
    url: "https://doi.org/10.1007/s11060-014-1510-6"
  },
  "207": {
    text: "Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovò MG. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):789–93.",
    url: "https://doi.org/10.1016/s0360-3016(98)00457-x"
  },
  "208": {
    text: "Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. J Clin Oncol. 2006 Sep 20;24(27):4412–7.",
    url: "https://doi.org/10.1200/jco.2006.06.9104"
  },
  "209": {
    text: "Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, et al. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2023 May 1;9(5):656–63.",
    url: "https://doi.org/10.1001/jamaoncol.2023.0056"
  },
  "210": {
    text: "Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):535–41.",
    url: "https://jamanetwork.com/journals/jamaoncology/fullarticle/2761664"
  },
  "211": {
    text: "Meattini I, Desideri I, Di Cataldo V, Francolini G, De Luca Cardillo C, Scotti V, et al. Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience and review of the literature. Future Oncol Lond Engl. 2016 May;12(9):1117–24.",
    url: "https://doi.org/10.2217/fon-2015-0059"
  },
  "212": {
    text: "Salama MM, Ghorab EM, Al-Abyad AG, Al-Bahy KM. Concomitant weekly vincristine and radiation followed by adjuvant vincristine and carboplatin in the treatment of high risk medulloblastoma: Ain Shams University Hospital and Sohag Cancer Center study. J Egypt Natl Cancer Inst. 2006 Jun;18(2):167–74.",
    url: "https://pubmed.ncbi.nlm.nih.gov/17496943/"
  },
  "213": {
    text: "Singhal N, Mislang A, Karapetis CS, Stephens S, Borg M, Woodman RJ, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anticancer Drugs. 2015 Nov;26(10):1083–8.",
    url: "https://doi.org/10.1159/000092062"
  },
  "214": {
    text: "Arnold CR, Lindner AK, Schachtner G, Tulchiner G, Tulchiner N, Mangesius J, et al. Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients? Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 Jan;198(1):25–32.",
    url: "https://doi.org/10.1007/s00066-021-01837-7"
  },
  "215": {
    text: "Nguyen PL, Kollmeier M, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).",
    url: "https://doi.org/10.1200/JCO.2023.41.6_suppl.303"
  },
  "216": {
    text: "Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, et al. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.",
    url: "https://doi.org/10.1016/j.euo.2024.06.013"
  },
  "217": {
    text: "Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.",
    url: "https://doi.org/10.1200/jco.22.01662"
  },
  "218": {
    text: "Sargos P, Bellera C, Bentahila R, Guerni M, Benziane-Ouaritini N, Teyssonneau D, et al. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.",
    url: "https://doi.org/10.1016/j.euo.2024.04.023"
  },
  "219": {
    text: "Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer.",
    url: "https://doi.org/10.1016/s0140-6736(21)02437-5"
  },
  "220": {
    text: "Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).",
    url: "https://doi.org/10.1200/jco.23.00985"
  },
  "221": {
    text: "Wang J, Yang Q, Haffty BG, Li X, Moran MS. Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells. Biochem Biophys Res Commun. 2013 Feb 8;431(2):146–51.",
    url: "https://doi.org/10.1016/j.bbrc.2013.01.006"
  },
  "222": {
    text: "Ding J, Guo Y, Jiang X, Li K, Fu W, Cao Y. Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer.",
    url: "https://doi.org/10.1097/MD.0000000000021344"
  },
  "223": {
    text: "Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.",
    url: "https://doi.org/10.1016/s1470-2045(10)70013-9"
  },
  "224": {
    text: "Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol. 2017;7:88.",
    url: "https://doi.org/10.3389/fonc.2017.00088"
  },
  "225": {
    text: "Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, et al. Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. J Thorac Dis. 2017 Nov;9(11):E985–9.",
    url: "https://doi.org/10.21037/jtd.2017.09.74"
  },
  "226": {
    text: "Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, Lipson KE, et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.",
    url: "https://doi.org/10.1016/j.radonc.2014.12.009"
  },
  "227": {
    text: "Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.",
    url: "https://doi.org/10.1016/j.ijrobp.2013.11.010"
  },
  "228": {
    text: "Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.",
    url: "https://doi.org/10.1158/1078-0432.ccr-13-0306"
  },
  "229": {
    text: "Stagno F, Vigneri P, Fabro VD, Stella S, Restuccia N, Giallongo C, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.",
    url: "https://doi.org/10.3109/02841860903302913"
  },
  "230": {
    text: "Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.",
    url: "https://doi.org/10.1016/j.radonc.2015.07.025"
  },
  "231": {
    text: "Cote GM, Barysauskas CM, DeLaney TF, Schwab J, Raskin K, Lozano-Calderon S, et al. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma.",
    url: "https://doi.org/10.1016/j.ijrobp.2018.07.2013"
  },
  "232": {
    text: "Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Biomed Pharmacother Biomedecine Pharmacother. 2020 Aug;128:110133.",
    url: "https://doi.org/10.1016/j.biopha.2020.110133"
  },
  "233": {
    text: "De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.",
    url: "https://doi.org/10.1186/s13014-017-0893-x"
  },
  "234": {
    text: "Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, et al. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer: a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.",
    url: "https://doi.org/10.1016/S1470-2045(22)00763-X"
  },
  "235": {
    text: "Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol. 2017;7:88.",
    url: "https://doi.org/10.3389/fonc.2017.00088"
  },
"125": {
    text: "Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2013 Aug;24(8):2088–92",
    url: "https://doi.org/10.1093/annonc/mdt140"
  },
  "286": {
    text: "Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers. 2021 May 15;13(10):2394.",
    url: "https://doi.org/10.3390/cancers13102394"
  },
  "236": {
    text: "Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023 Jun 8;115(6):742–8.",
    url: "https://doi.org/10.1093/jnci/djac015"
  },
  "237": {
    text: "Wang N, Wang L, Meng X, Wang J, Zhu L, Liu C, et al. Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. Oncol Rep. 2019 Jan;41(1):77–86.",
    url: "https://doi.org/10.3892/or.2018.6804"
  },
  "238": {
    text: "Zhai X, Li W, Li J, Jia W, Jing W, Tian Y, et al. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Radiat Oncol Lond Engl. 2021 Dec 5;16(1):233.",
    url: "https://doi.org/10.1186/s13014-021-01960-w"
  },
  "239": {
    text: "Khan M, Zhao Z, Arooj S, Zheng T, Liao G. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis. Front Oncol. 2020 Nov 6;10:576926.",
    url: "https://doi.org/10.3389/fonc.2020.576926"
  },
  "240": {
    text: "Ramesh S, Cifci A, Javeri S, Minne RL, Longhurst CA, Nickel KP, et al. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1379–90.",
    url: "https://doi.org/10.1016/j.ijrobp.2023.10.014"
  },
  "241": {
    text: "Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, et al. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2023 Apr;6(2):204–11.",
    url: "https://doi.org/10.1016/j.euo.2022.10.004"
  },
  "242": {
    text: "Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, et al. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15;122(4):582–7.",
    url: "https://doi.org/10.1002/cncr.29798"
  },
  "243": {
    text: "Olsen MR, Denu RA, Lyon JB, Gulliver JM, Capitini CM, DeSantes KB. Undifferentiated and Unresectable Sarcoma With NTRK3-Fusion in a Pediatric Patient Treated With Larotrectinib and Proton Beam Radiotherapy. J Pediatr Hematol Oncol. 2022 Apr 1;44(3):e770–4.",
    url: "https://doi.org/10.1097/mph.0000000000002358"
  },
  "244": {
    text: "Rao SS, Thompson C, Cheng J, Haimovitz-Friedman A, Powell SN, Fuks Z, et al. Axitinib sensitization of high Single Dose Radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014 Apr;111(1):88–93.",
    url: "https://doi.org/10.1016/j.radonc.2014.02.010"
  },
  "245": {
    text: "Hu K, Ma MW, Gao XS, Chen JY, Li XY, Qin SB, et al. Mid-Term Analysis of the Combination Therapy of Axitinib, Toripalimab, and Stereotactic Ablative Body Radiotherapy (SABR) in the Treatment of Recurrent Metastatic Renal Cell Carcinoma. Int J Radiat Oncol. 2024 Oct 1;120(2, Supplement):e538.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.07.1192"
  },
  "246": {
    text: "Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):719–32.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.09.060"
  },
  "247": {
    text: "Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol Lond Engl. 2023 Jun 12;18:101.",
    url: "https://doi.org/10.1186/s13014-023-02270-z"
  },
  "248": {
    text: "Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang K, Humm JL, et al. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat. 2021 Jul;188(2):415–24.",
    url: "https://doi.org/10.1007/s10549-021-06209-4"
  },
  "249": {
    text: "O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, et al. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res. 2017 Jul 15;77(14):3885–93.",
    url: "https://doi.org/10.1158/0008-5472.CAN-17-0082"
  },
  "250": {
    text: "Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28;306(2):223–9.",
    url: "https://doi.org/10.1016/j.canlet.2011.03.010"
  },
  "251": {
    text: "Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010 May;11(5):459–64.",
    url: "https://doi.org/10.1016/S1470-2045(10)70058-9"
  },
  "252": {
    text: "Shi W, Palmer JD, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, et al. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. J Neurooncol. 2016 May;127(3):535–9.",
    url: "https://doi.org/10.1007/s11060-016-2059-3"
  },
  "253": {
    text: "Drappatz J, Mantica M. Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas. J Clin Oncol. 2024 Jun 1;42(16_suppl):2040–2040.",
    url: "https://doi.org/10.1200/JCO.2024.42.16_suppl.2040"
  },
  "254": {
    text: "Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1192–7.",
    url: "https://doi.org/10.1016/j.ijrobp.2011.09.023"
  },
  "255": {
    text: "Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):433–9.",
    url: "https://doi.org/10.1016/j.ijrobp.2008.08.050"
  },
  "256": {
    text: "Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, et al. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol Lond Engl. 2013 Aug 21;8:204.",
    url: "https://doi.org/10.1186/1748-717x-8-204"
  },
  "257": {
    text: "Pollom EL, Bui TT, Chang ALS, Colevas AD, Hara WY. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatol. 2015 Sep;151(9):998–1001.",
    url: "https://doi.org/10.1001/jamadermatol.2015.0326"
  },
  "258": {
    text: "Barker CA, Dufault S, Arron ST, Ho AL, Algazi AP, Dunn LA, et al. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. J Clin Oncol. 2024 Jul;42(19):2327–35.",
    url: "https://doi.org/10.1200/jco.23.01708"
  },
  "259": {
    text: "Wang K, Patel M, Prabhu AV, Lewis GD. First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma. Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol. 2021;26(1):149–52.",
    url: "https://doi.org/10.5603/RPOR.a2021.0010"
  },
  "260": {
    text: "Day D, Prawira A, Spreafico A, Waldron J, Karithanam R, Giuliani M, et al. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncol. 2020 Sep;108:104753.",
    url: "https://doi.org/10.1016/j.oraloncology.2020.104753"
  },
  "261": {
    text: "Gryc T, Putz F, Goerig N, Ziegler S, Fietkau R, Distel LV, et al. Idelalisib may have the potential to increase radiotherapy side effects. Radiat Oncol Lond Engl. 2017 Jun 28;12(1):109.",
    url: "https://doi.org/10.1186/s13014-017-0827-7"
  },
  "262": {
    text: "König L, Dreyling M, Dürig J, Engelhard M, Hohloch K, Viardot A, et al. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial. Trials. 2019 Aug 30;20(1):544.",
    url: "https://doi.org/10.1186/s13063-019-3614-y"
  },
  "263": {
    text: "Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, et al. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. HemaSphere. 2018 Nov 30;2(6):e160.",
    url: "https://doi.org/10.1097/HS9.0000000000000160"
  },
  "264": {
    text: "Debbi K, Loganadane G, Roulin L, Belhadj K, Boukhobza C, Saoudi A, et al. Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe! Rep Pract Oncol Radiother. 2024;29(3):408–10.",
    url: "https://doi.org/10.5603/rpor.100780"
  },
  "265": {
    text: "Lee YL, Hsu JF, Yang CJ. Tracheoesophageal Fistula in a Patient with Advanced Non–Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab. J Thorac Oncol. 2019 Jan 1;14(1):e17–8.",
    url: "https://doi.org/10.1016/j.jtho.2018.08.2031"
  },
  "266": {
    text: "Akahane K, Shirai K, Wakatsuki M, Ogawa K, Minato K, Hamamoto K, et al. Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy. Clin Case Rep. 2020;8(5):919–27.",
    url: "https://doi.org/10.1002/ccr3.2751"
  },
  "267": {
    text: "Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222–7.",
    url: "https://doi.org/10.1016/j.ijrobp.2008.03.046"
  },
  "268": {
    text: "Bohli M, Jaffel H, El Fida Noubbigh G, Tbessi S, Msadek F, Kochbati L. Synergistic Effect and Tolerance of Concurrent Radiotherapy and Lenalidomide Use in Relapsing Mantle Cell Lymphoma: A Case Report. Perm J. 2020 Nov;24:1–6.",
    url: "https://doi.org/10.7812/tpp/19.156"
  },
  "269": {
    text: "Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Feb 20;30(6):616–22.",
    url: "https://doi.org/10.1200/jco.2011.36.9116"
  },
  "270": {
    text: "Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. Cancer. 2008 Oct 15;113(8):2139–42.",
    url: "https://doi.org/10.1002/cncr.23805"
  },
  "271": {
    text: "Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, et al. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2006 Feb;36(2):93–9.",
    url: "https://doi.org/10.1093/jjco/hyi242"
  },
  "272": {
    text: "Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 2008 Jul 15;68(14):5915–23.",
    url: "https://doi.org/10.1158/0008-5472.can-08-0757"
  },
  "273": {
    text: "Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, et al. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol. 2015 Jun 1;26(6):1223–9.",
    url: "https://doi.org/10.1093/annonc/mdv105"
  },
  "274": {
    text: "Eren MF, Ay Eren A, Sayan M, Yücel B, Elagöz Ş, Özgüven Y, et al. The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. Medicina (Mex). 2020 Jul 13;56(7):348.",
    url: "https://doi.org/10.3390/medicina56070348"
  },
  "275": {
    text: "Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, et al. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Adv Radiat Oncol. 2023;8(6):101279.",
    url: "https://doi.org/10.1016/j.adro.2023.101279"
  },
  "276": {
    text: "Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458–64.",
    url: "https://doi.org/10.1182/blood-2016-03-703470"
  },
  "277": {
    text: "Bouziane J, Loap P, Cao K, Allali S, Gounane Y, Loganadane G, et al. Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature. Am J Clin Oncol. 2024 Dec;47(12):580.",
    url: "https://doi.org/10.1097/coc.0000000000001135"
  },
  "278": {
    text: "Soni YS, Lock D, Ballas LK, Hwang L, Cole S, D'Souza A, et al. Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer. Int J Radiat Oncol Biol Phys. 2024 Oct 1;120(2):S74–5.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.07.129"
  },
  "279": {
    text: "Seyedin SN, Harada GK, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, et al. Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2024 Dec 1;22(6):102243.",
    url: "https://doi.org/10.1016/j.clgc.2024.102243"
  },
  "280": {
    text: "Krug D, Tio J, Abaci A, Beurer B, Brügge S, Elsayad K, et al. The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study. Cancers. 2024 Apr 25;16(9):1649.",
    url: "https://doi.org/10.3390/cancers16091649"
  },
  "281": {
    text: "Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers. 2021 May 15;13(10):2394.",
    url: "https://doi.org/10.3390/cancers13102394"
  },
  "282": {
    text: "Banla LI, Tzeng A, Baillieul JP, Kandekhar MJ, Fitzgerald KJ, LoPiccolo J, et al. Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO Clin Res Rep. 2023 Oct;4(10):100559.",
    url: "https://doi.org/10.1016/j.jtocrr.2023.100559"
  },
  "283": {
    text: "Smith CP, Abtin F, Xiang M, Yoon S, Ruan D, Goldman J, et al. Incidence of Radiation Pneumonitis Among Patients Treated with Concurrent Thoracic Radiotherapy and Osimertinib for Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol. 2022 Nov 1;114(3, Supplement):e391.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.07.1516"
  },
  "284": {
    text: "Nepote A, Poletto S, Bertaglia V, Carnio S, Piumatti C, Lanzetta C, et al. Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review. Crit Rev Oncol Hematol. 2024 Oct 30;205:104540.",
    url: "https://doi.org/10.1016/j.critrevonc.2024.104540"
  },
  "285": {
    text: "Xu Y, Qie W, Yu J, Wang L. Risk factors and clinical characteristics of pneumonitis among patients with ALK-rearranged non-small cell lung cancer who received alectinib and thoracic radiotherapy. J Clin Oncol. 2022 Jun;40(16_suppl):e20591–e20591.",
    url: "https://doi.org/10.1200/JCO.2022.40.16_suppl.e20591"
  },


    }
